Without fanfare, the University of Pennsylvania has agreed to invest up to $50 million over the next three years in at least 10 biotech companies, the Inquirer has learned.
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of Eversense®, a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that it has commenced a registered underwritten public offering of $80 million of its shares of common stock. In addition, Senseonics has granted the underwriter a 30-day option to purchase up to an additional $12 million of its shares of common stock. All of the shares to be sold in the offering are to be sold by Senseonics.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today introduced seamless next-generation sequencing (NGS) solutions for a wide range of hereditary diseases on the GeneReader NGS System, the complete Sample to Insight NGS solution for any lab worldwide.
Hospitals in D.C. and Baltimore rank among the best in the nation, according to a new list released by U.S. News & World Report.
Overall, Children’s National Medical Center in D.C. ranked No. 5 and John’s Hopkins Children’s Center in Baltimore ranked No. 8 on the “honor roll,” which lists the best-performing children’s hospitals across 10 pediatric specialties including neonatal care, neurology, cancer and cardiology.
Joel Grimwood needed a new heart, but a chronic bacterial infection lurking within his implanted ventricle assist device made getting one impossible. Five transplant centers declined his case due to his persistent infection. Then Grimwood came to UC San Diego Health, where doctors treated the infection with an experimental bacteriophage therapy – viruses that eat bacteria. The infection cleared and Grimwood got his new heart.
The University of California San Diego launched the Center for Innovative Phage Applications and Therapeutics (IPATH) to develop bacteriophages to fight multidrug-resistant bacteria. The initial focus will be on treating chronic infections associated with cystic fibrosis, organ transplantation and implantable hardware. The center hopes to start clinical trials by year end.
What started with a wife’s stubborn refusal to give up on her husband who lay dying of a superbug infection has become a whole new research initiative at UC San Diego.
One piece of good news can make all the difference. In the fight against antibiotic-resistant infections, a decades-old approach based on bacteria-slaying viruses called phages has been sidelined by technical hurdles, dogged by regulatory confusion, and largely ignored by drug developers in the West. But 2 years ago, researchers at the University of California, San Diego (UCSD), used phages to knock out an infection that nearly killed a colleague. Propelled by that success and a handful of others since, UCSD is now launching a clinical center to refine phage treatments and help companies bring them to market.
A new medical research center in San Diego is embracing an innovative way to treat antibiotic resistant infections called bacteriophage therapy—phage therapy for short—which uses viruses as weapons against hard-to-treat infections.
When her husband was dying of a drug-resistant infection, Steffanie Strathdee had a last-ditch idea. They could try treating him with a virus that would kill the bacteria colonizing his insides. The method, called phage therapy, was popular in former Soviet republics, but had mostly been abandoned in the U.S. Researchers had to hunt for the right virus in Texas pigsties and sewage treatment plants.